Trials / Completed
CompletedNCT00125723
FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,252 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the impact of first and subsequent cycle pegfilgrastim on neutropenia events (such as hospitalizations, dose reductions and delays) in patients receiving myelosuppressive chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | PI Discretion | PI Discretion |
Timeline
- Start date
- 2004-05-01
- Primary completion
- 2005-12-01
- Completion
- 2005-12-01
- First posted
- 2005-08-02
- Last updated
- 2010-12-23
Source: ClinicalTrials.gov record NCT00125723. Inclusion in this directory is not an endorsement.